Tyrosinemia type 3

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:69723OMIM:276710E70.2
Who is this for?
Show terms as
6Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Tyrosinemia type 3 (also called HT3 or hydroxyphenylpyruvate dioxygenase deficiency) is a very rare inherited metabolic disorder. It happens when the body cannot properly break down the amino acid tyrosine, which is a building block of protein found in many foods. The problem is caused by a missing or poorly working enzyme called 4-hydroxyphenylpyruvate dioxygenase (HPPD). Without this enzyme working correctly, tyrosine and its byproducts build up to harmful levels in the blood and urine. The most noticeable effects of tyrosinemia type 3 are on the brain and nervous system. Many people with this condition experience intellectual disability, seizures, and problems with coordination and balance. Unlike the other types of tyrosinemia, this form does not usually cause serious liver or kidney damage, which makes it somewhat different in how it affects the body. Treatment mainly focuses on reducing tyrosine levels through a special low-protein diet and a formula that limits the amino acids phenylalanine and tyrosine. There is no specific FDA-approved drug for this exact condition. With careful dietary management, some symptoms may be reduced, but neurological problems can still persist. Because this disease is so rare, research is ongoing and management is largely guided by metabolic specialists.

Also known as:

Key symptoms:

Intellectual disability or learning difficultiesSeizures or epilepsyProblems with balance and coordination (ataxia)Elevated tyrosine levels in the bloodHigh levels of tyrosine byproducts in the urineDevelopmental delaysBehavioral problemsMild movement difficulties

Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Tyrosinemia type 3.

View clinical trials →

No actively recruiting trials found for Tyrosinemia type 3 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Tyrosinemia type 3 community →

Specialists

6 foundView all specialists →
GD
Gary Hubbard, Dr
Birmingham
Specialist

Rare Disease Specialist

PI on 1 active trial
AM
Anita MacDonald
Birmingham
Specialist

Rare Disease Specialist

PI on 10 active trials
EM
Erik Brouwer, MD
Specialist
PI on 1 active trial
JA
Jean-Baptiste Arnoux
Specialist
PI on 1 active trial27 Tyrosinemia type 3 publications
AM
Anders Bröijersén, MD
Specialist
PI on 1 active trial1 Tyrosinemia type 3 publication

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Tyrosinemia type 3.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Tyrosinemia type 3Forum →

No community posts yet. Be the first to share your experience with Tyrosinemia type 3.

Start the conversation →

Latest news about Tyrosinemia type 3

No recent news articles for Tyrosinemia type 3.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How often should we check blood tyrosine levels, and what is the target range?,What specific foods and proteins should be avoided or limited in the diet?,Will the dietary treatment improve or prevent further neurological problems?,What seizure medications are recommended, and what should we do in a seizure emergency?,Are there any clinical trials or new treatments we should know about?,What developmental or educational support services do you recommend?,Should other family members be tested for this condition?

Common questions about Tyrosinemia type 3

What is Tyrosinemia type 3?

Tyrosinemia type 3 (also called HT3 or hydroxyphenylpyruvate dioxygenase deficiency) is a very rare inherited metabolic disorder. It happens when the body cannot properly break down the amino acid tyrosine, which is a building block of protein found in many foods. The problem is caused by a missing or poorly working enzyme called 4-hydroxyphenylpyruvate dioxygenase (HPPD). Without this enzyme working correctly, tyrosine and its byproducts build up to harmful levels in the blood and urine. The most noticeable effects of tyrosinemia type 3 are on the brain and nervous system. Many people with t

How is Tyrosinemia type 3 inherited?

Tyrosinemia type 3 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Tyrosinemia type 3 typically begin?

Typical onset of Tyrosinemia type 3 is infantile. Age of onset can vary across affected individuals.

Which specialists treat Tyrosinemia type 3?

6 specialists and care centers treating Tyrosinemia type 3 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.